BiotechTube

Isatuximab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AL Amyloidosis

Conditions

AL Amyloidosis

Trial Timeline

Feb 11, 2022 → Mar 1, 2026

NCT ID
NCT05066607

About Isatuximab

Isatuximab is a phase 2 stage product being developed by Bristol Myers Squibb for AL Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05066607. Target conditions include AL Amyloidosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05066607Phase 2Recruiting

Competing Products

20 competing products in AL Amyloidosis

See all competitors
ProductCompanyStageHype Score
ZN-d5Zentalis PharmaceuticalsPhase 1/2
33
VELCADEJohnson & JohnsonPhase 1/2
41
ABBV-383 (Etentamig)AbbViePhase 1/2
41
Venetoclax + Dexamethasone + DaratumumabAbbViePhase 1/2
41
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
23
Carfilzomib + DexamethasoneAmgenPhase 1
32
IdelalisibGilead SciencesPhase 2
51
TafamidisPfizerPre-clinical
22
TafamidisPfizerPre-clinical
22
Fx-1006APfizerPhase 2
51
tafamidisPfizerPre-clinical
22
Cyclophosphamide + Dexamethasone + Elotuzumab + LenalidomideBristol Myers SquibbPhase 2
51
Bortezomib + Cyclophosphamide + Dexamethasone + IsatuximabSanofiPhase 1
32
Bendamustine Hydrochloride + IsatuximabSanofiPhase 2
51
NC-503 (Anti-amyloidotic (AA) Agent)GSK plcPhase 2/3
64
NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
76
LinvoseltamabRegeneron PharmaceuticalsPhase 1/2
40
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
30
PatisiranAlnylam PharmaceuticalsPhase 3
74

Other Products from Bristol Myers Squibb

DeucravacitinibApproved
84
Aripiprazole + Olanzapine + HaloperidolApproved
84
Irbesartan + CiprofibrateApproved
84
Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved
84
deucravacitinibApproved
84